Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Pediatric Solid Tumors
Interventions
DRUG

perifosine + temsirolimus

The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

University of Wisconsin, Madison

OTHER

collaborator

Duke University

OTHER

collaborator

NATL COMP CA NETWORK

UNKNOWN

collaborator

Pfizer

INDUSTRY

collaborator

AEterna Zentaris

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER